Drug Profile
RBM 005
Alternative Names: RBM-005Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Ribomic
- Class Anti-infectives; Antifibrotics; Peptide aptamers
- Mechanism of Action High mobility group protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Fibrosis; Sepsis
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Fibrosis in Japan (unspecified route)
- 11 Sep 2023 Discontinued - Preclinical for Sepsis in Japan (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Fibrosis in Japan